Engineering c-Met-CAR NK-92 cells as a promising therapeutic candidate for lung adenocarcinoma
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Engineering c-Met-CAR NK-92 cells as a promising therapeutic candidate for lung adenocarcinoma
Authors
Keywords
-
Journal
PHARMACOLOGICAL RESEARCH
Volume 188, Issue -, Pages 106656
Publisher
Elsevier BV
Online
2023-01-12
DOI
10.1016/j.phrs.2023.106656
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Emerging Role of c-Met in Carcinogenesis and Clinical Implications as a Possible Therapeutic Target
- (2022) Antonio Faiella et al. Journal of Oncology
- Next Generation Natural Killer Cells for Cancer Immunotherapy
- (2022) Fiorella Rossi et al. Frontiers in Immunology
- Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision
- (2022) Gillianne GY Lai et al. CANCER TREATMENT REVIEWS
- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- NK cell-based cancer immunotherapy: from basic biology to clinical development
- (2021) Sizhe Liu et al. Journal of Hematology & Oncology
- Cytokines in CAR T Cell–Associated Neurotoxicity
- (2021) Juliane Gust et al. Frontiers in Immunology
- Quaking 5 suppresses TGF‐β‐induced EMT and cell invasion in lung adenocarcinoma
- (2021) Shengjie Wang et al. EMBO REPORTS
- Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
- (2021) Ying Gong et al. Journal of Hematology & Oncology
- CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies
- (2021) Faroogh Marofi et al. Stem Cell Research & Therapy
- A novel chimeric PD1-NKG2D-41BB receptor enhances antitumor activity of NK92 cells against human lung cancer H1299 cells by triggering pyroptosis
- (2020) Chengui Lu et al. MOLECULAR IMMUNOLOGY
- Targeting B7-H3 Immune Checkpoint With Chimeric Antigen Receptor-Engineered Natural Killer Cells Exhibits Potent Cytotoxicity Against Non-Small Cell Lung Cancer
- (2020) Shuo Yang et al. Frontiers in Pharmacology
- Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives
- (2020) Jingjing Qu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Exploring the NK cell platform for cancer immunotherapy
- (2020) Jacob A. Myers et al. Nature Reviews Clinical Oncology
- Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer
- (2020) May Daher et al. Cancer Discovery
- Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy
- (2019) Jianguang Zhang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients
- (2019) Lin Xiao et al. MOLECULAR THERAPY
- Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
- (2019) Mohamed-Reda Benmebarek et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- ROR1 associates unfavorable prognosis and promotes lymphoma growth in DLBCL by affecting PI3K/Akt/mTOR signaling pathway
- (2019) Yuan Mao et al. BIOFACTORS
- 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies
- (2019) Yingxi Xu et al. Journal of Hematology & Oncology
- c-Met and PD-L1 on Circulating Exosomes as Diagnostic and Prognostic Markers for Pancreatic Cancer
- (2019) Alexander Lux et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy
- (2019) Kyle B. Lupo et al. Cancers
- High-Affinity Human Anti-c-Met IgG Conjugated to Oxaliplatin as Targeted Chemotherapy for Hepatocellular Carcinoma
- (2019) Yilan Ma et al. Frontiers in Oncology
- MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells
- (2019) Yuan Mao et al. Journal of Hematology & Oncology
- The Prognostic Role of MET Protein Expression Among Surgically Resected Non-small Cell Lung Cancer Patients: A Meta-Analysis
- (2019) Guangzhi Ma et al. Frontiers in Oncology
- Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity
- (2018) Ye Li et al. Cell Stem Cell
- Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering
- (2018) May Daher et al. CURRENT OPINION IN IMMUNOLOGY
- ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway
- (2018) Andrew M. Kidger et al. PHARMACOLOGY & THERAPEUTICS
- GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
- (2018) Rosalie M. Sterner et al. BLOOD
- Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells
- (2018) Jiao Wang et al. Journal for ImmunoTherapy of Cancer
- Integrator orchestrates RAS/ERK1/2 signaling transcriptional programs
- (2017) Jingyin Yue et al. GENES & DEVELOPMENT
- Lung cancer: current therapies and new targeted treatments
- (2017) Fred R Hirsch et al. LANCET
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Overexpression of MAGE-A9 predicts unfavorable outcome in breast cancer
- (2014) Xin Xu et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cellsviacMet pathway through HGF-dependent and -independent mechanisms
- (2014) Isabelle Matte et al. INTERNATIONAL JOURNAL OF CANCER
- MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation
- (2014) Ling Huang et al. Journal of Thoracic Oncology
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- A novel human Fab antibody for Trop2 inhibits breast cancer growthin vitroandin vivo
- (2013) Hong Lin et al. INTERNATIONAL JOURNAL OF CANCER
- Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
- (2013) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes
- (2012) K. P. Raghav et al. CLINICAL CANCER RESEARCH
- Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
- (2011) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- c-MET as a potential therapeutic target and biomarker in cancer
- (2011) J. Rafael Sierra et al. Therapeutic Advances in Medical Oncology
- Targeting Fibroblast Growth Factor Receptors Blocks PI3K/AKT Signaling, Induces Apoptosis, and Impairs Mammary Tumor Outgrowth and Metastasis
- (2010) J. H. Dey et al. CANCER RESEARCH
- Comprehensive Molecular Analyses of Lung Adenocarcinoma with Regard to the Epidermal Growth Factor Receptor, K-ras, MET, and Hepatocyte Growth Factor Status
- (2010) Takamitsu Onitsuka et al. Journal of Thoracic Oncology
- Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors
- (2008) P. A. Zucali et al. ANNALS OF ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More